Industry news, page-1836

We need to take a very thoughtful approach so that we generate the data that will attract both regulator and partner support. Everyone we speak to accepts bisantrene works as an anticancer agent, thinks it highly likely that adding it to doxorubicin will provide better anticancer outcomes, the real question comes around its ability to protect the heart from doxorubicin.

While the data we have suggests this heart-protecting property is plausible, there is no clinical data (yet) that supports this hypothesis. This is why we are concentrating on getting this clinical data as soon as possible. The good news is we should get at least preliminary data out of the Phase 1 trial and that the Phase 1 trial is fully funded.